SCHEMBL6182495

SCHEMBL6182495

CC(CCNC(=O)c1ccc(-c2ncc[nH]2)cc1)CC(=O)NCC#N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
F10 P00742 3/20 0.44
MAPK14 Q16539 2/20 0.42
PRSS1 P07477 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
CTSB P07858 1/20 0.37
NEK1 Q96PY6 1/20 0.37
HTT P42858 1/20 0.37
FASN P49327 1/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
NAMPT P43490 1/20 0.35
NISCH Q9Y2I1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182813 0.89 MAP3K5 (0.43) F10MAPK14CTSBHTTNAMPT
SCHEMBL7554411 0.81 EPHX2 (0.50) ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL6183366 0.80 NPC1 (0.40) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7452326 0.78 SMN1; SMN2 (0.42) NPC1RAB9ASMN1; SMN2CTSB
SCHEMBL6182799 0.78 LMNA (0.45) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7452250 0.76 HDAC1 (0.49) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7450457 0.76 MCHR1 (0.43) NPC1RAB9ASMN1; SMN2CTSB
SCHEMBL7452860 0.75 KDM4E (0.60) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7450325 0.75 ALDH1A1 (0.47) KDM4EALDH1A1MAPK14NPC1RAB9A
SCHEMBL6183157 0.75 KDM4E (0.60) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
US-20020086996-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 US disclosed
EP-1161415-A2 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-12 EP disclosed
WO-2000055126-A2 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086996-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 KDM4E 2428/4885ALDH1A1 4049/4885F10 2065/4885
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 KDM4E 2428/4885ALDH1A1 4049/4885F10 2065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.